Nicotine and Harm Reduction Panel
The FDA has approved two rounds of MRTP marketing orders, with several pending applications and more to come. Panelists will discuss the role of the MRTP process in risk communication, post-market surveillance requirements, and the extent that marketing orders can or should impact applications for other similar products.
Moderated by Barry Schaevitz, Partner, Fox Rothschild LLP
Jonathan Foulds, Professor of Public Health Sciences and Psychiatry, Penn State University College of Medicine
Joe Murillo, Chief Regulatory Officer, JUUL Labs Inc.
John Pritchard, Vice President of Regulatory Science, 22nd Century Group